 |
110 Diseases |  |
151 Trials |
|
151 Trials |  |
7120 News |  |
| «12...75767778798081828384858687» |
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab (clinicaltrials.gov) - Sep 28, 2014
P2, N=96, Completed, Sponsor: Amgen
Active, not recruiting --> Completed
- Prolia (denosumab) / Amgen, Daiichi Sankyo
HEOR: Effectiveness or Orthopedic Intervention in Osteoporosis Management After a Fracture of the Hip With Cost-Benefit Analysis (clinicaltrials.gov) - Sep 12, 2014
P=N/A, N=360, Not yet recruiting, Sponsor: Shaare Zedek Medical Center
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion, Trial initiation date, Trial primary completion date: RA Denosumab on Bone Microstructure Study (clinicaltrials.gov) - Sep 11, 2014
P4, N=40, Completed, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Completed Not yet recruiting --> Completed | Initiation date: Sep 2013 --> Dec 2012 | Trial primary completion date: Sep 2014 --> Jun 2014
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients (clinicaltrials.gov) - Sep 8, 2014
P4, N=100, Recruiting, Sponsor: Shinshu University
Not yet recruiting --> Completed | Initiation date: Sep 2013 --> Dec 2012 | Trial primary completion date: Sep 2014 --> Jun 2014 Trial primary completion date: May 2014 --> Sep 2014
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: China HVT Safety, PK, PD (clinicaltrials.gov) - Sep 4, 2014
P1, N=64, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: May 2014 --> Sep 2014 Recruiting --> Active, not recruiting
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, Enrollment closed, IO biomarker: Effect of Denosumab on Cellular Biomarkers in the Human Breast (clinicaltrials.gov) - Aug 6, 2014
P1, N=82, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed, Enrollment change: A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Aug 1, 2014
P3, N=394, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=300 --> 394
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed, Trial primary completion date: Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients (clinicaltrials.gov) - Jul 30, 2014
P3, N=90, Active, not recruiting, Sponsor: Rudolf Wuethrich
Recruiting --> Active, not recruiting | N=300 --> 394 Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2015
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: China HVT Safety, PK, PD (clinicaltrials.gov) - Jul 29, 2014
P1, N=64, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2015 Not yet recruiting --> Recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo, Samcyprone (diphenylcyclopropenone) / Phio Pharma
Trial completion, Trial primary completion date, IO biomarker: Effect of RANKL Inhibition on UV-induced Immunosuppression (clinicaltrials.gov) - Jul 24, 2014
P1, N=31, Completed, Sponsor: Innovaderm Research Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Oct 2014 --> Jun 2014
- | Prolia (denosumab) / Amgen
Enrollment open, Trial initiation date, Head-to-Head: REDUSE: Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks (clinicaltrials.gov) - Jul 18, 2014
P3, N=1380, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Recruiting --> Completed | Trial primary completion date: Oct 2014 --> Jun 2014 Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Jul 2014
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer (clinicaltrials.gov) - Jul 16, 2014
P3, N=1435, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Jul 2014 Active, not recruiting --> Completed
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Jul 1, 2014
P4, N=68, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: Denosumab and Teriparatide Study (DATA-HD and DATA-EX) (clinicaltrials.gov) - Jun 27, 2014
P4, N=70, Not yet recruiting, Sponsor: Massachusetts General Hospital
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer (clinicaltrials.gov) - Jun 26, 2014
P3, N=18, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical: Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=500, Recruiting, Sponsor: Tomidahama Hospital
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P3 trial: A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Jun 4, 2014
P3, N=300, Recruiting, Sponsor: Amgen
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients (clinicaltrials.gov) - Jun 3, 2014
P4, N=100, Recruiting, Sponsor: Shinshu University
- || Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion date: Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density (clinicaltrials.gov) - May 8, 2014
P2, N=419, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Trial completion date: Mar 2014 --> Apr 2016
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date, Metastases: Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease (clinicaltrials.gov) - May 8, 2014
P4, N=100, Not yet recruiting, Sponsor: Amgen
Trial completion date: Mar 2014 --> Apr 2016 Initiation date: Apr 2014 --> May 2014
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P1 trial: China HVT Safety, PK, PD (clinicaltrials.gov) - May 8, 2014
P1, N=64, Not yet recruiting, Sponsor: GlaxoSmithKline
- ||||||| Prolia (denosumab) / Amgen
Trial completion, Metastases: AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer (clinicaltrials.gov) - May 7, 2014
P3, N=1468, Completed, Sponsor: Amgen
Initiation date: Apr 2014 --> May 2014 Active, not recruiting --> Completed
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion date: Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer (clinicaltrials.gov) - May 7, 2014
P3, N=1435, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Trial completion date: Feb 2014 --> Jun 2014
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab (clinicaltrials.gov) - May 4, 2014
P4, N=60, Recruiting, Sponsor: Health Research, Inc.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial: SALTIRE II: Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis. (clinicaltrials.gov) - May 4, 2014
P2, N=150, Not yet recruiting, Sponsor: University of Edinburgh
- |||||||||| Prolia (denosumab) / Amgen
New P3 trial, Metastases: SPLENDOUR: Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy (clinicaltrials.gov) - Apr 30, 2014
P3, N=1000, Not yet recruiting, Sponsor: European Thoracic Oncology Platform
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, Trial initiation date, IO biomarker: Effect of Denosumab on Cellular Biomarkers in the Human Breast (clinicaltrials.gov) - Apr 28, 2014
P1, N=72, Recruiting, Sponsor: Amgen
Trial completion date: Feb 2014 --> Jun 2014 Initiation date: Mar 2014 --> Apr 2014
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, Enrollment open, IO biomarker: Effect of Denosumab on Cellular Biomarkers in the Human Breast (clinicaltrials.gov) - Apr 28, 2014
P1, N=72, Recruiting, Sponsor: Amgen
Initiation date: Mar 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, Trial initiation date: Denosumab for Breast Cancer With Bone Mets (clinicaltrials.gov) - Apr 24, 2014
P2, N=35, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Initiation date: Mar 2014 --> Jul 2014
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date: Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product (clinicaltrials.gov) - Apr 23, 2014
P1, N=140, Recruiting, Sponsor: Amgen
Initiation date: Mar 2014 --> Jul 2014 Initiation date: Jan 2014 --> Feb 2014
- ||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial, Metastases: Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease (clinicaltrials.gov) - Mar 31, 2014
P4, N=100, Not yet recruiting, Sponsor: Amgen
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, New P1 trial, IO biomarker: Effect of Denosumab on Cellular Biomarkers in the Human Breast (clinicaltrials.gov) - Mar 27, 2014
P1, N=72, Recruiting, Sponsor: Amgen
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects. (clinicaltrials.gov) - Mar 24, 2014
P3, N=2049, Completed, Sponsor: Amgen
Initiation date: Jan 2014 --> Feb 2014 Active, not recruiting --> Completed
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Mar 16, 2014
P4, N=68, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab (clinicaltrials.gov) - Mar 5, 2014
P2, N=10, Active, not recruiting, Sponsor: University of Cologne
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||||| Prolia (denosumab) / Amgen
Trial completion: Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma. (clinicaltrials.gov) - Mar 3, 2014
P3, N=1779, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Enrollment closed: FRAME: Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Mar 2, 2014
P3, N=7180, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis (clinicaltrials.gov) - Mar 2, 2014
P4, N=40, Active, not recruiting, Sponsor: Tuen Mun Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P1 trial: Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product (clinicaltrials.gov) - Feb 2, 2014
P1, N=140, Recruiting, Sponsor: Amgen
- || Prolia (denosumab) / Amgen
New P3 trial, Head-to-Head: REDUSE: Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks (clinicaltrials.gov) - Jan 29, 2014
P3, N=1380, Not yet recruiting, Sponsor: Swiss Group for Clinical Cancer Research
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2b trial: Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP (clinicaltrials.gov) - Jan 28, 2014
P2b, N=40, Not yet recruiting, Sponsor: Elizabeth Shane
- ||| Prolia (denosumab) / Amgen
Enrollment closed: Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Jan 28, 2014
P4, N=643, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose (clinicaltrials.gov) - Jan 28, 2014
P1, N=12, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed, Metastases: ABCSG-18: Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy (clinicaltrials.gov) - Jan 22, 2014
P3, N=3425, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Prolia (denosumab) / Amgen
Trial completion: Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium (clinicaltrials.gov) - Jan 12, 2014
P2, N=33, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Denosumab China Phase III Study (clinicaltrials.gov) - Jan 8, 2014
P3, N=444, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date: ProliaHip: Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women (clinicaltrials.gov) - Jan 6, 2014
P4, N=68, Recruiting, Sponsor: Turku University Hospital
Not yet recruiting --> Recruiting Initiation date: Sep 2013 --> Dec 2013
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: ProliaHip: Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women (clinicaltrials.gov) - Jan 6, 2014
P4, N=68, Recruiting, Sponsor: Turku University Hospital
Initiation date: Sep 2013 --> Dec 2013 Not yet recruiting --> Recruiting
- | Prolia (denosumab) / Amgen
Enrollment change: Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only (clinicaltrials.gov) - Dec 18, 2013
P3, N=35, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting N=100 --> 35
- || Prolia (denosumab) / Amgen
Trial completion: Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only (clinicaltrials.gov) - Dec 18, 2013
P3, N=35, Completed, Sponsor: Amgen
N=100 --> 35 Active, not recruiting --> Completed